Source of the article: Device Career
Reprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.
On July 15, 2024, Johnson & Johnson announced that Edward Zhou (Zhou Mintao) would serve asUnder its umbrellaPresident of Medical Technology, China RegionOne position, reporting to Vishnu Karla, Chair of Johnson & Johnson MedTech Asia Pacific, and becoming one of the members of the Johnson & Johnson MedTech Asia Pacific leadership team.
On April 23, 2024, Johnson & Johnson announcedChairman of China Region, President of Johnson & Johnson Medical Technology China, Song WeiqunNews of Departure.
22003,Song WeiqunJoining Johnson & Johnson at its U.S. headquarters as the only global management trainee that year, Will Song's resume lists just one company: Johnson & Johnson.
The first China-born chairman of Johnson & Johnson's China region.
The news of Song Weiqun's departure has drawn widespread attention in the industry. Meanwhile, the selection of the next president of Johnson & Johnson Medical (China) Ltd. has also become a hot topic of discussion.
And the addition of Zhou Mintao has broughtThe Answer to the Johnson & Johnson Medical China Leadership, Which Had Been Hanging for About 3 Months, Is Now Clear.
# Johnson & Johnson Veteran Returns
Zhou Mintao graduated from the Biochemistry program at Fudan University in 1990, joined Johnson & Johnson in 1992, and served the Chinese market for over a decade. From 2007 to 2009, he served as the General Manager of Johnson & Johnson Singapore.
During his nearly 30-year tenure at Johnson & Johnson, Zhou Mintao has been a widely respected leader.
He started as a sales representative in Johnson & Johnson's consumer products business, gradually took on more responsibilities, and was sent to the UK to participate in the International Development Program. He later became the General Manager of Johnson & Johnson's consumer products business in Singapore. After returning to China, Edward led the company’s acquisition of Dabao and successfully integrated it into Johnson & Johnson. In the following three years, he served as the General Manager of Johnson & Johnson's consumer products business in China.
In 2015, Edward joined Johnson & Johnson Medical (China) Ltd., serving as the Vice President of Surgical Business for Ethicon Division, and in 2016, he became the General Manager of Ethicon Division in China.During this period, he promoted continuous business innovation, accelerated market penetration, optimized product portfolios, drove digital transformation, and facilitated the localized smart manufacturing of advanced surgical products at the Suzhou Industrial Park. Over his seven-year tenure, he led the team to achieve an annual compound growth rate of 15%.
At the end of 2021, Zhou Mintao left Johnson & Johnson Medical and joined Danaher as President of China Biotechnology Platform and President of Cytiva Greater China., and subsequently led the team to complete the integration of the company with Pall Life Sciences.
On February 21, 2024, Zhou Mintao bid farewell to Danaher employees via an internal email: After careful consideration, he decided to temporarily step away from over three decades of full-time career to devote more time and energy to family and personal interests.
Now, Zhou Mintao has returned to Johnson & Johnson, serving as the President of Johnson & Johnson Medical Technology in China. His management style and high emphasis on talent cultivation will play a significant role in continuing to advance in China, which is the second-largest market for Johnson & Johnson Medical Technology globally.
# About Johnson & Johnson China
In 1985, as one of the first multinational enterprises to enter the Chinese market since the reform and opening up, Johnson & Johnson established Xi'an Janssen Pharmaceutical Co., Ltd. in China. Today, all of Johnson & Johnson's global businesses—including medical devices, pharmaceuticals, consumer health products, and Vision—are present in China. Currently, Johnson & Johnson has over 10 legal entities and 9 supply chain bases in China, located in cities such as Beijing, Shanghai, Guangzhou, Suzhou, and Xi’an, with approximately 11,000 employees.Johnson & Johnson Medical (China) Ltd. was established on November 10, 1994, under Johnson & Johnson of the United States, primarily engaging in medical device-related businesses in China (hereinafter referred to as Johnson & Johnson MedTech China).Johnson & Johnson provides a series of innovative products for medical professionals. The main products of Johnson & Johnson Medical (China) Ltd. include: medical devices used in minimally invasive and open surgeries (such as wound closure, staplers, ultrasonic scalpels, and absorbable hemostatic gauze), electrophysiology (such as catheters and related technologies), orthopedics (such as joint reconstruction, trauma, spine, sports medicine, maxillofacial, and power tools), plastic surgery (such as breast implants), and other fields.Johnson & Johnson Medical (China) Ltd.Johnson & Johnson Medical (China) Ltd. was established on November 10, 1994, under Johnson & Johnson of the United States, and primarily engages in medical device-related businesses in China (hereinafter referred to as Johnson & Johnson Medical China).Johnson & Johnson Medical (China) Ltd. mainly focuses on medical devices used in minimally invasive and open surgeries (such as wound closure, staplers, harmonic scalpels, and absorbable hemostatic gauze), electrophysiology (such as catheters and related technologies), orthopedics (such as joint reconstruction, trauma, spine, sports medicine, maxillofacial, and power tools), and plastic surgery (such as breast implants).Johnson & Johnson Medical (China) Ltd. currently has more than 3,500 employees, with its headquarters in Shanghai and offices in Beijing, Guangzhou, Wuhan, Nanjing, Jinan, Hangzhou, Chongqing, Chengdu, Xi'an, Tianjin, and other cities. It is committed to providing high-quality products and services to patients in China while continuously introducing the latest medical technologies and equipment into the country.Johnson & Johnson Medical (Suzhou) Ltd.Johnson & Johnson (Suzhou) Medical Devices Co., Ltd. was established in 2006 in the Suzhou Industrial Park and is the largest comprehensive industrial park of Johnson & Johnson Medical in China (hereinafter referred to as: Johnson & Johnson Suzhou Industrial Park).As an important part of Johnson & Johnson's global medical supply chain, the Johnson & Johnson Suzhou Industrial Park simultaneously houses DePuySynthes orthopedic surgical instruments andEthiconTwo Major Manufacturing Plants for Surgical Instruments, with the Capacity to Accommodate More Production of Johnson & Johnson Medical Device Brands. DePuySynthes has Eleven Years of High-Quality Manufacturing Experience in the Johnson & Johnson Suzhou Industrial Park, Primarily Producing Orthopedic Surgical Instruments Such as Joint Replacement and Spinal Repair Products, Which are Supplied Globally. In January 2019, the Johnson & Johnson Medical Ethicon New Factory in Suzhou was Officially Established, Dedicated to High-Quality, Innovative Absorbable Surgical Sutures.StaplerAnd other products.Johnson & Johnson Medical R&D (Suzhou) CenterOpened in Suzhou in 2011, it conducts local insights and innovative R&D of medical device products tailored to the unique needs of customers and patients in the Asia-Pacific emerging markets, especially in China, to better respond to the growing and evolving healthcare demands in the Chinese market.Johnson & Johnson Vision Care (Shanghai) Co., Ltd.Johnson & Johnson Vision Care (Shanghai) Co., Ltd. is inJohnson & Johnson Group in ChinaA subsidiary company operating Johnson & Johnson Acuvue® replacement contact lenses in the Chinese market, with headquarters in Jacksonville, Florida, USA.
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
